New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:08 EDTTSROTESARO and AnaptysBio collaborate on immuno-oncology antibody program
TESARO and AnaptysBio announced a strategic immuno-oncology collaboration under which AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody candidates from these programs are expected to enter clinical trials over the next 18 to 24 months. TESARO will pay an upfront license fee of $17M and provide funding of costs incurred by AnaptysBio related to the development programs. For each development program, AnaptysBio is eligible to receive milestone payments associated with certain U.S. and ex-U.S. regulatory submissions and approvals in multiple indications. AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
07:02 EDTTSROTESARO 3.4M share Secondary priced at $51.00
Subscribe for More Information
March 2, 2015
16:22 EDTTSROTESARO files to sell $150M of common stock
Subscribe for More Information
February 23, 2015
06:25 EDTTSROMedivation removed from Focus List at Citigroup
Subscribe for More Information
06:23 EDTTSROCiti ups TESARO price target to $79, adds to focus list
Subscribe for More Information
February 20, 2015
05:53 EDTTSROTESARO price target raised to $50 from $44 at Mizuho
Mizuho raised its price target for TESARO shares to $50 citing increased confidence and market opportunity for niraparib following the company's Q4 results. The firm expects approval for rolapitant in Q3 and reiterates a Buy rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use